Genetic factors associated with naevus count and dermoscopic patterns: Preliminary results from the Study of Nevi in Children (SONIC)

British Journal of Dermatology

Volumn 172, Issue 4, 2015, Pages 1081-1089

  Orlow, I ^a   Satagopan, J M ^a   Berwick, M ^b   Enriquez, H L ^a   White, K A M ^b   Cheung, K ^a   Dusza, S W ^a   Oliveria, S A ^a   Marchetti, M A ^a   Scope, A ^a,c   Marghoob, A A ^a   Halpern, A C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1B; INTERFERON REGULATORY FACTOR 4; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TELOMERASE REVERSE TRANSCRIPTASE; CDK6 PROTEIN, HUMAN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4; MELANOCORTIN 1 RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; PHOSPHOLIPASE A2 GROUP VI; PLA2G6 PROTEIN, HUMAN;

ARTICLE; CHILD; COHORT ANALYSIS; CUTANEOUS PARAMETERS; DNA POLYMORPHISM; EPILUMINESCENCE MICROSCOPY; ETHNICITY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOCYTIC NEVUS; MELANOMA; NAEVUS COUNT; PRIORITY JOURNAL; RACE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ADVERSE EFFECTS; ALLELE; GENETICS; GENOTYPE; PATHOLOGY; PIGMENTED NEVUS; PROCEDURES; PROSPECTIVE STUDY; SKIN TUMOR; SUNLIGHT;

ALLELES; CHILD; CYCLIN-DEPENDENT KINASE 6; DERMOSCOPY; FEMALE; GENETIC LOCI; GENOTYPE; GROUP VI PHOSPHOLIPASES A2; HUMANS; INTERFERON REGULATORY FACTORS; MALE; NEVUS, PIGMENTED; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECEPTOR, MELANOCORTIN, TYPE 1; SKIN NEOPLASMS; SUNLIGHT;

EID: 84926209648     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13467     Document Type: Article

References (57)

1. Gandini S, Sera F, Cattaruzza MS, et al,. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41: 28-44.
2. Bauer J, Buttner P, Wiecker TS, et al,. Risk factors of incident melanocytic nevi: a longitudinal study in a cohort of 1,232 young German children. Int J Cancer 2005; 115: 121-6.
3. English DR, Milne E, Simpson JA,. Ultraviolet radiation at places of residence and the development of melanocytic nevi in children (Australia). Cancer Causes Control 2006; 17: 103-7.
4. Oliveria SA, Satagopan JM, Geller AC, et al,. Study of Nevi in Children (SONIC): baseline findings and predictors of nevus count. Am J Epidemiol 2009; 169: 41-53.
5. Scope A, Marghoob AA, Dusza SW, et al,. Dermoscopic patterns of naevi in fifth grade children of the Framingham school system. Br J Dermatol 2008; 158: 1041-9.
6. English DR, Armstrong BK,. Melanocytic nevi in children. I. Anatomic sites and demographic and host factors. Am J Epidemiol 1994; 139: 390-401.
7. Bataille V, Snieder H, MacGregor AJ, et al,. Genetics of risk factors for melanoma: an adult twin study of nevi and freckles. J Natl Cancer Inst 2000; 92: 457-63.
8. Easton DF, Cox GM, Macdonald AM, Ponder BA,. Genetic susceptibility to naevi-a twin study. Br J Cancer 1991; 64: 1164-7.
9. Zhu G, Duffy DL, Eldridge A, et al,. A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet 1999; 65: 483-92.
10. Barrett JH, Iles MM, Harland M, et al,. Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet 2011; 43: 1108-13.
11. Duffy DL, Box NF, Chen W, et al,. Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum Mol Genet 2004; 13: 447-61.
12. Barrett EL, Burke TA, Hammers M, et al,. Telomere length and dynamics predict mortality in a wild longitudinal study. Mol Ecol 2013; 22: 249-59.
13. Bodelon C, Pfeiffer RM, Bollati V, et al,. On the interplay of telomeres, nevi and the risk of melanoma. PLoS One 2012; 7: e52466.
14. Nan H, Qureshi AA, Prescott J, et al,. Genetic variants in telomere-maintaining genes and skin cancer risk. Hum Genet 2011; 129: 247-53.
15. Duffy DL, Zhao ZZ, Sturm RA, et al,. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 2010; 130: 520-8.
16. Liang X, Pfeiffer RM, Li WQ, et al,. Association of genetic variants in CDK6 and XRCC1 with the risk of dysplastic nevi in melanoma-prone families. J Invest Dermatol 2014; 134: 481-7.
17. Argenziano G, Zalaudek I, Ferrara G, et al,. Proposal of a new classification system for melanocytic naevi. Br J Dermatol 2007; 157: 217-27.
18. Scope A, Dusza SW, Marghoob AA, et al,. Clinical and dermoscopic stability and volatility of melanocytic nevi in a population-based cohort of children in Framingham school system. J Invest Dermatol 2011; 131: 1615-21.
19. Scope A, Marghoob AA, Chen CS, et al,. Dermoscopic patterns and subclinical melanocytic nests in normal-appearing skin. Br J Dermatol 2009; 160: 1318-21.
20. Piliouras P, Gilmore S, Wurm EM, et al,. New insights in naevogenesis: number, distribution and dermoscopic patterns of naevi in the elderly. Australas J Dermatol 2011; 52: 254-8.
21. Zalaudek I, Argenziano G, Mordente I, et al,. Nevus type in dermoscopy is related to skin type in white persons. Arch Dermatol 2007; 143: 351-6.
22. Zalaudek I, Grinschgl S, Argenziano G, et al,. Age-related prevalence of dermoscopy patterns in acquired melanocytic naevi. Br J Dermatol 2006; 154: 299-304.
23. Zalaudek I, Schmid K, Marghoob AA, et al,. Frequency of dermoscopic nevus subtypes by age and body site: a cross-sectional study. Arch Dermatol 2011; 147: 663-70.
24. Zalaudek I, Ferrara G, Argenziano G,. Dermoscopy insights into nevogenesis: 'Abtropfung' versus 'Hochsteigerung'. Arch Dermatol 2007; 143: 284.
25. Zalaudek I, Hofmann-Wellenhof R, Kittler H, et al,. A dual concept of nevogenesis: theoretical considerations based on dermoscopic features of melanocytic nevi. J Dtsch Dermatol Ges 2007; 5: 985-92.
26. Geller AC, Oliveria SA, Bishop M, et al,. Study of health outcomes in school children: key challenges and lessons learned from the Framingham Schools' Natural History of Nevi Study. J Sch Health 2007; 77: 312-18.
27. Hofmann-Wellenhof R, Blum A, Wolf IH, et al,. Dermoscopic classification of atypical melanocytic nevi (Clark nevi). Arch Dermatol 2001; 137: 1575-80.
28. O'Brien KM, Orlow I, Antonescu CR, et al,. Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants. PLoS One 2013; 8: e62119.
29. Orlow I, Roy P, Reiner AS, et al,. Vitamin D receptor polymorphisms in patients with cutaneous melanoma. Int J Cancer 2012; 130: 405-18.
30. Satagopan JM, Zhou Q, Oliveria SA, et al,. Properties of preliminary test estimators and shrinkage estimators for evaluating multiple exposures-application to questionnaire data from the SONIC study. J R Stat Soc Ser C Appl Stat 2011; 60: 619-32.
31. Efron B, Tibshirani RJ,. An Introduction to the Bootstrap. New York: Chapman & Hall, 1993.
32. Sturm RA, Larsson M,. Genetics of human iris colour and patterns. Pigment Cell Melanoma Res 2009; 22: 544-62.
33. Kvaskoff M, Whiteman DC, Zhao ZZ, et al,. Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma. Twin Res Hum Genet 2011; 14: 422-32.
34. Praetorius C, Grill C, Stacey SN, et al,. A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell 2013; 155: 1022-33.
35. Sundram U, Harvell JD, Rouse RV, Natkunam Y,. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol 2003; 16: 802-10.
36. Tanaka N, Taniguchi T,. The interferon regulatory factors and oncogenesis. Semin Cancer Biol 2000; 10: 73-81.
37. Do TN, Ucisik-Akkaya E, Davis CF, et al,. An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males. Biochim Biophys Acta 2010; 1802: 292-300.
38. Han J, Qureshi AA, Nan H, et al,. A germline variant in the interferon regulatory factor 4 gene as a novel skin cancer risk locus. Cancer Res 2011; 71: 1533-9.
39. Zhang M, Song F, Liang L, et al,. Genome-wide association studies identify several new loci associated with pigmentation traits and skin cancer risk in European Americans. Hum Mol Genet 2013; 22: 2948-59.
40. Wesierska-Gadek J, Ranftler C, Schmid G,. Physiological ageing: role of p53 and PARP-1 tumor suppressors in the regulation of terminal senescence. J Physiol Pharmacol 2005; 56 (Suppl. 2): 77-88.
41. Bouchard VJ, Rouleau M, Poirier GG,. PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 2003; 31: 446-54.
42. Luo X, Kraus WL,. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 2012; 26: 417-32.
43. Rosado MM, Bennici E, Novelli F, Pioli C,. Beyond DNA repair, the immunological role of PARP-1 and its siblings. Immunology 2013; 139: 428-37.
44. Staibano S, Pepe S, Lo Muzio L, et al,. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol 2005; 36: 724-31.
45. Macgregor S, Montgomery GW, Liu JZ, et al,. Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet 2011; 43: 1114-18.
46. Pena-Chilet M, Blanquer-Maceiras M, Ibarrola-Villava M, et al,. Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population. BMC Cancer 2013; 13: 160.
47. Nan H, Xu M, Zhang J, et al,. Genome-wide association study identifies nidogen 1 (NID1) as a susceptibility locus to cutaneous nevi and melanoma risk. Hum Mol Genet 2011; 20: 2673-9.
48. Melin BS, Nordfjall K, Andersson U, Roos G,. hTERT cancer risk genotypes are associated with telomere length. Genet Epidemiol 2012; 36: 368-72.
49. Newton-Bishop JA, Chang YM, Iles MM, et al,. Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom. Cancer Epidemiol Biomarkers Prev 2010; 19: 2043-54.
50. Yang XR, Liang X, Pfeiffer RM, et al,. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations. Fam Cancer 2010; 9: 625-33.
51. Bishop DT, Demenais F, Iles MM, et al,. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009; 41: 920-5.
52. Falchi M, Bataille V, Hayward NK, et al,. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 2009; 41: 915-19.
53. Gerstenblith MR, Shi J, Landi MT,. Genome-wide association studies of pigmentation and skin cancer: a review and meta-analysis. Pigment Cell Melanoma Res 2010; 23: 587-606.
54. Bassoli S, Maurichi A, Rodolfo M, et al,. CDKN2A and MC1R variants influence dermoscopic and confocal features of benign melanocytic lesions in multiple melanoma patients. Exp Dermatol 2013; 22: 411-16.
55. Sturm RA, Fox C, McClenahan P, et al,. Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. J Invest Dermatol 2014; 134: 141-9.
56. Oliveria SA, Geller AC, Dusza SW, et al,. The Framingham school nevus study: a pilot study. Arch Dermatol 2004; 140: 545-51.
57. Pellacani G, Scope A, Ferrari B, et al,. New insights into nevogenesis: in vivo characterization and follow-up of melanocytic nevi by reflectance confocal microscopy. J Am Acad Dermatol 2009; 61: 1001-13.